Trading Report: Today, Intercept Pharmaceuticals Inc. (ICPT) CMO Sold $63,022.74 in Stock

Today, Intercept Pharmaceuticals Inc. (ICPT) CMO Sold $63,022.74 in Stock

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) CMO David Shapiro sold 411 shares of the stock in a transaction that occurred on Monday, October 10th. The shares were sold at an average price of $153.34, for a total transaction of $63,022.74. Following the sale, the chief marketing officer now directly owns 44,272 shares of the company’s stock, valued at $6,788,668.48. The sale was disclosed in a document filed with the SEC, which is available through this link.

David Shapiro also recently made the following trade(s): On Monday, October 3rd, David Shapiro sold 1,513 shares of Intercept Pharmaceuticals stock. The shares were sold at an average price of $163.08, for a total transaction of $246,740.04. On Monday, September 26th, David Shapiro sold 3,545 shares of Intercept Pharmaceuticals stock. The shares were sold at an average price of $165.08, for a total transaction of $585,208.60.

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) opened at 142.47 on Monday. The stock’s market cap is $3.52 billion. The stock’s 50 day moving average price is $155.48 and its 200 day moving average price is $151.28. Intercept Pharmaceuticals Inc. has a 52 week low of $89.76 and a 52 week high of $217.99.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($3.14) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($3.69) by $0.55. The company earned $5.52 million during the quarter, compared to analysts’ expectations of $1.72 million. Intercept Pharmaceuticals had a negative return on equity of 50.58% and a negative net margin of 5,003.95%. The firm’s quarterly revenue was up 1140.4% on a year-over-year basis. During the same period in the prior year, the business earned ($1.99) EPS. On average, analysts forecast that Intercept Pharmaceuticals Inc. will post ($16.31) earnings per share for the current year.

A number of hedge funds have recently modified their holdings of ICPT. Public Employees Retirement Association of Colorado raised its position in shares of Intercept Pharmaceuticals by 0.3% in the second quarter. Public Employees Retirement Association of Colorado now owns 4,075 shares of the biopharmaceutical company’s stock valued at $581,000 after buying an additional 14 shares during the period. Metropolitan Life Insurance Co. NY raised its position in shares of Intercept Pharmaceuticals by 3.2% in the second quarter. Metropolitan Life Insurance Co. NY now owns 1,234 shares of the biopharmaceutical company’s stock valued at $176,000 after buying an additional 38 shares during the period. Wedbush Securities Inc. raised its position in shares of Intercept Pharmaceuticals by 1.8% in the second quarter. Wedbush Securities Inc. now owns 2,260 shares of the biopharmaceutical company’s stock valued at $322,000 after buying an additional 40 shares during the period. Sheaff Brock Investment Advisors LLC raised its position in shares of Intercept Pharmaceuticals by 1.2% in the second quarter. Sheaff Brock Investment Advisors LLC now owns 4,350 shares of the biopharmaceutical company’s stock valued at $621,000 after buying an additional 50 shares during the period. Finally, Legal & General Group Plc raised its position in shares of Intercept Pharmaceuticals by 4.5% in the second quarter. Legal & General Group Plc now owns 1,196 shares of the biopharmaceutical company’s stock valued at $171,000 after buying an additional 52 shares during the period. Institutional investors own 81.83% of the company’s stock.

A number of research firms have recently commented on ICPT. Wedbush reiterated a “buy” rating and set a $239.00 target price on shares of Intercept Pharmaceuticals in a research report on Saturday, July 9th. Leerink Swann reiterated a “positive” rating on shares of Intercept Pharmaceuticals in a research report on Friday. Credit Suisse Group AG reiterated a “buy” rating and set a $200.00 target price on shares of Intercept Pharmaceuticals in a research report on Friday, August 5th. Laidlaw downgraded Intercept Pharmaceuticals from a “buy” rating to a “sell” rating and lowered their target price for the company from $345.00 to $105.00 in a research report on Friday, August 5th. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $218.00 target price (down from $219.00) on shares of Intercept Pharmaceuticals in a research report on Friday, August 5th. Five investment analysts have rated the stock with a sell rating, four have issued a hold rating and eleven have issued a buy rating to the company. Intercept Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $177.67.

Intercept Pharmaceuticals Company Profile

Related posts

Leave a Comment